Fig. 4

FOXP2 mediates transcriptional repression of CEP55. A, The intersection of transcription factors regulating CEP55 downloaded from the hTFtarget database, differentially expressed genes in the GSE119054 dataset, and Differential Genes downloaded from the GEPIA database. B, Expression of FOXP2 in ovarian serous cystadenocarcinoma analyzed by the GEPIA database. C, ChIP-seq database analysis of FOXP2 enrichment in the CEP55 promoter. D, Jaspar database analysis of FOXP2 binding sites in the CEP55 promoter. E, RT-qPCR detection of FOXP2 expression in tumor tissues and adjacent tissues of OC patients. F, Correlation between FOXP2 and CEP55 expression in OC tissues (n = 19) analyzed using Pearson’s correlation analysis. G, Expression of FOXP2 and CEP55 in cells after overexpression of FOXP2 in A2780 and SKOV3 cells detected by RT-qPCR. H, Luciferase activity in A2780 and SKOV3 cells was assessed using a dual-luciferase reporter assay. I, The binding of FOXP2 to the CEP55 promoter was analyzed using ChIP assay. Statistical significance was assessed using an unpaired t-test or ANOVA. **p < 0.01, ***p < 0.001, ****p < 0.0001. All cell experiments were repeated three times